Jump to content
RemedySpot.com

Administration of interferon for two or more years decreases early stage hepatocellular carcinoma recurrence rate after radical ablation: A retrospective study of hepatitis C virus-related liver cancer

Rate this topic


Recommended Posts

Posted

http://onlinelibrary.wiley.com/doi/10.1111/j.1872-034X.2010.00720.x/abstract

Administration of interferon for two or more years decreases early stage

hepatocellular carcinoma recurrence rate after radical ablation: A retrospective

study of hepatitis C virus-related liver cancer

Kenji Ikeda, Masahiro Kobayashi, Yuya Seko, Norihiro Imai, Miharu Hirakawa,

Yusuke Kawamura, Hitomi Sezaki, Tetsuya Hosaka, Norio Akuta, Satoshi Saitoh,

Fumitaka Suzuki, Yoshiyuki Suzuki, Yasuji Arase, Hiromitsu KumadaArticle first

published online: 16 SEP 2010

DOI: 10.1111/j.1872-034X.2010.00720.x

© 2010 The Japan Society of Hepatology

Issue

Hepatology Research

Early View (Articles online in advance of print)

Background:  Since hepatocellular carcinoma often recurs after surgical

resection or radiofrequency ablation, we analyzed a retrospective large cohort

of patients with small hepatocellular carcinoma caused by hepatitis C virus

(HCV).

Methods:  Among 379 patients with HCV RNA-positive small hepatocellular

carcinoma (multiple up to three nodules, 3 cm or less each), 77 received

interferon-alpha injection and 302 received no anti-viral therapy.

Results:  Four patients (5.2%) attained sustained virological response (SVR).

Cumulative recurrence rates in the treated and untreated groups were 41.1% and

57.5% at the end of the third year, and 63.0% and 74.5% at the fifth year,

respectively (P = 0.013). Fifth year-recurrence rates in treated group were

25.0% in SVR, 85.7% in biochemical response, 71.1% in no response, and 46.7% in

patients with continuous administration. When four patients with SVR were

excluded, recurrence rates in short-term interferon therapy (<2 years) and

long-term therapy (≥2 years) were 46.2% and 39.3% at the third year, and 66.2%

and 57.4% at the fifth year, respectively (P = 0.012). Multivariate analysis

showed that long-term interferon therapy significantly decreased recurrence rate

(hazard ratio for interferon <2 years 0.80, interferon ≥2 years 0.60, P =

0.044), after adjustment with background covariates including indocyanine green

retention rate (P = 0.018), alpha-fetoprotein (P = 0.051), and tumor treatment

(P = 0.066).

Conclusion:  A long-term administration of low-dose interferon significantly

decreased recurrence of hepatocellular carcinoma after surgical resection or

radiofrequency ablation.

Join the conversation

You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.

Guest
Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

Loading...
×
×
  • Create New...